Plitidepsin: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis2 studies · 163 patientsc19early.org

Plitidepsin for COVID-19

Serious outcome risk
Plitidepsin
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (2)−16%
Mortality (2)−16%
RCTs (2)−16%
RCT mortality (2)−16%
Peer-reviewed (1)1%
Late (2)−16%
00.511.5+
← Plitidepsin
reduces riskIncreased
risk →
c19early.org
October 2026

Plitidepsin COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Landete (RCT)1%0.99 · 0.14–6.79death2/682/67NEPTUNO PharmaMar (RCT)−36%1.36 · 0.19–9.57death5/221/6NEREIDA
Late treatment−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Plitidepsin
reduces riskPlitidepsin
increases risk →
c19early.org
October 2026

Plitidepsin COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Landete (RCT)1%0.99 · 0.14–6.792/682/67NEPTUNO PharmaMar (RCT)−36%1.36 · 0.19–9.575/221/6NEREIDA
Late treatment−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Plitidepsin
reduces riskPlitidepsin
increases risk →
c19early.org
October 2026

Plitidepsin COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Landete (RCT)1%0.99 · 0.14–6.79death2/682/67NEPTUNO PharmaMar (RCT)−36%1.36 · 0.19–9.57death5/221/6NEREIDA
Late treatment−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Plitidepsin
reduces riskPlitidepsin
increases risk →
c19early.org
October 2026

Plitidepsin COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Landete (RCT)1%0.99 · 0.14–6.79death2/682/67NEPTUNO PharmaMar (RCT)−36%1.36 · 0.19–9.57death5/221/6NEREIDA
Late treatment−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Plitidepsin
reduces riskPlitidepsin
increases risk →
c19early.org
October 2026

Plitidepsin COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Landete (RCT)1%0.99 · 0.14–6.792/682/67NEPTUNO PharmaMar (RCT)−36%1.36 · 0.19–9.575/221/6NEREIDA
Late treatment−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−16%1.16 · 0.29–4.567/903/7316% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Plitidepsin
reduces riskPlitidepsin
increases risk →
c19early.org
October 2026

Plitidepsin COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Landete (RCT)1%0.99 · 0.14–6.79death2/682/67NEPTUNO
Late treatment1%0.99 · 0.14–6.792/682/671% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.99
All studies1%0.99 · 0.14–6.792/682/671% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.9900.511.52+
Rotate screen for more detailsIncrease width for more details
← Plitidepsin
reduces riskPlitidepsin
increases risk →